Clinical data | |
---|---|
Trade names | Ojemda |
Other names | BIIB-024, MLN2480, AMG 2112819, DAY101, TAK-580 |
License data |
|
Routes of administration | By mouth |
Drug class | Antineoplastic |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ChEMBL |
|
PDB ligand |
|
Chemical and physical data | |
Formula | C17H12Cl2F3N7O2S |
Molar mass | 506.29 g·mol−1 |
InChI
|
Tovorafenib, sold under the brand name Ojemda, is a medication used for the treatment of glioma.[1] It is a kinase inhibitor.[1]
The most common adverse reactions include rash, hair color changes, fatigue, viral infection, vomiting, headache, hemorrhage, pyrexia, dry skin, constipation, nausea, dermatitis acneiform, and upper respiratory tract infection.[2] The most common grade 3 or 4 laboratory abnormalities include decreased phosphate, decreased hemoglobin, increased creatinine phosphokinase, increased alanine aminotransferase, decreased albumin, decreased lymphocytes, decreased leukocytes, increased aspartate aminotransferase, decreased potassium, and decreased sodium.[2]
It was approved for medical use in the United States in April 2024,[1][2][3][4] and is the first approval of a systemic therapy for the treatment of people with pediatric low-grade glioma with BRAF rearrangements, including fusions.[2]